EQ Equillium, Inc.

Nasdaq equilliumbio.com


$ 1.05 $ -0.01 (-0.93 %)    

Monday, 17-Nov-2025 12:45:04 EST
QQQ $ 605.75 $ -0.38 (-0.06 %)
DIA $ 469.81 $ -1.05 (-0.22 %)
SPY $ 668.68 $ -1.00 (-0.15 %)
TLT $ 89.14 $ 0.06 (0.07 %)
GLD $ 374.69 $ 0.69 (0.18 %)
$ 1.04
$ 1.06
$ 1.04 x 886
$ 1.07 x 100
$ 1.04 - $ 1.15
$ 0.27 - $ 2.35
1,352,251
na
63.33M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-25-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-23-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-24-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-27-2019 12-31-2018 10-K
29 11-15-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 equillium-files-for-mixed-shelf-of-up-to-250m

-SEC Filing

 equillium-files-prospectus-for-75m-share-offering

-SEC Filing

 equillium-files-for-offering-of-up-to-5263m-shares-of-common-stock-by-selling-stockholders

-SEC Filing

 why-is-equillium-stock-soaring-monday

Equillium stock is trading higher Monday after the company announced up to $50 million in financing through a securities purcha...

 equillium-announces-strategic-expansion-to-integrate-cryptocurrency-treasury-reserve-strategy-as-part-of-its-broader-financial-and-growth-objectives

Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory d...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION